Children with intestinal failure who are receiving parenteral nutrition through a central venous catheter are at risk of developing catheter-related bloodstream infections. For many years, a prophylactic lock with taurolidine has been used to decrease the incidence of these infections and is considered safe in children.
Case Presentation:
A 1-month-old boy with jejunal atresia was receiving parenteral nutrition through a central venous catheter. Shortly after administration of taurolidine (TauroSept®), he developed circulatory insufficiency and angioedema. His serum tryptase increased, which was suggestive of anaphylaxis (baseline tryptase 6.3 µg/L; 2 h after start of the reaction: 21 µg/L; cutoff criterion for clinically relevant increase: 1.2 × baseline tryptase level + 2).
Conclusions:
To the best of our knowledge, this is the first case of anaphylaxis in response to TauroSept® in an infant worldwide. Clinicians should be aware of this possible but very rare side effect.
ChuH-P, BrindJ, TomarR, et al.Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. J Pediatr Gastroenterol Nutr, 2012; 55(4):403–407; doi: 10.1097/MPG.0b013e31825bb0ae
3.
LambeC, PoissonC, TalbotecC, et al.Strategies to reduce catheter-related bloodstream infections in pediatric patients receiving home parenteral nutrition: The efficacy of taurolidine-citrate prophylactic-locking. JPEN J Parenter Enteral Nutr, 2018; 42(6):1017–1025; doi: 10.1002/jpen.1043
4.
SavareseI, YazamiS, De RoseDU, et al.Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: A feasibility study. J Hosp Infect, 2024; 143:76–81; doi: 10.1016/j.jhin.2023.11.003
5.
KolačekS, PuntisJWL, HojsakI, ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Venous access. Clin Nutr, 2018; 37(6 Pt B):2379–2391; doi: 10.1016/j.clnu.2018.06.952
6.
BartonA. A guide to: Catheter lock solutions for the prevention of CRBSI. Br J Nurs, 2019; 28(Sup19):2–8; doi: 10.12968/bjon.2019.28.Sup19.1
7.
ValentP, BonadonnaP, HartmannK, et al.Why the 20% + 2 Tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol, 2019; 180(1):44–51; doi: 10.1159/000501079
8.
HammondC. Revisiting the definition of anaphylaxis. Curr Allergy Asthma Rep, 2023; 23(5):249–254; doi: 10.1007/s11882-023-01077-y
9.
GreenhawtM, GuptaRS, MeadowsJA, et al.Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: An expert panel consensus. J Allergy Clin Immunol Pract, 2019; 7(4):1148–1156; doi: 10.1016/j.jaip.2018.10.052
10.
NaranjoCA, BustoU, SellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30(2):239–245; doi: 10.1038/clpt.1981.154
11.
FrancoisF, MauffBL, WaeckelL, et al.; French Network of Hospital Biologist in Allergology (AllergoBioNet). Basal serum tryptase: A critical reconsideration of reference values. Allergy, 2023; 78(11):3003–3006; doi: 10.1111/all.15790
Atanaskovic-MarkovicM, GomesE, CernadasJR, et al.Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper. Pediatr Allergy Immunol, 2019; 30(3):269–276; doi: 10.1111/pai.13034
15.
PedrosaC, CostaH, OliveiraG, et al.Anaphylaxis to povidone in a child. Pediatr Allergy Immunol, 2005; 16(4):361–362; doi: 10.1111/j.1399-3038.2005.00272.x
16.
DümichenMJ, SeegerK, LodeHN, et al.Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect, 2012; 80(4):304–309; doi: 10.1016/j.jhin.2012.01.003
17.
SimonA, AmmannRA, WiszniewskyG, et al.Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis, 2008; 8:102; doi: 10.1186/1471-2334-8-102
18.
WoutersY, TheillaM, SingerP, et al.Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Aliment Pharmacol Ther, 2018; 48(4):410–422; doi: 10.1111/apt.14904
19.
KorziliusJW, GillisVELM, WoutersY, et al.Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems. Clin Nutr, 2022; 41(10):2178–2184; doi: 10.1016/j.clnu.2022.07.025
